Status:

RECRUITING

Pre-exposure Prophylaxis (PrEP) Adherence Intervention for Women with Substance Use Disorders

Lead Sponsor:

The University of Texas Health Science Center, Houston

Conditions:

Substance Use

Eligibility:

FEMALE

18-60 years

Phase:

NA

Brief Summary

The goal of this clinical trial is to test an addiction-clinic based behavioral intervention for increasing PrEP uptake and adherence among women who engage in high-risk sexual behaviors and problemat...

Eligibility Criteria

Inclusion

  • Black/African American and Hispanic/Latina cisgender women
  • diagnosed with a Substance use disorder (SUD) per Diagnostic and Statistical Manual of Mental Illnesses (DSM)-5 criteria
  • HIV negative
  • sexually active with an opposite sex partner within the past 6 months
  • not using PrEP for HIV prevention at the time of screening
  • able to speak, read, and write in English; and
  • own or have regular access to a smart phone.

Exclusion

  • be concurrently participating in another SUD behavioral treatment program
  • unable to provide informed consent for participation (e.g., have severe cognitive impairment that would interfere with their ability to consent, understand study procedures and/or effectively participate in therapy
  • have psychological distress that would prohibit them from participating in the study
  • be unable or unwilling to meet study requirements
  • be ineligible for PrEP based on Centers for Disease Control and Prevention (CDC)-defined criteria for PrEP based on substance use and sexual risk
  • have medical contraindications for PrEP (e.g., known renal impairment which can be exacerbated by PrEP use).

Key Trial Info

Start Date :

June 7 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 30 2025

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT06158607

Start Date

June 7 2022

End Date

May 30 2025

Last Update

December 30 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston

Houston, Texas, United States, 77054